Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-970"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20100922.20.3-970"2
lpv:hasSubsequent	lp_eu:2010-09-22-Speech-3-1962
lpv:speaker	lp:Alfredo Pallone2
lpv:spokenAs	member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2009-09-16--2014-06-30)3 member; ECON (2009-07-16--2012-01-18)3 substitute; Delegation for relations with Canada (2009-09-16--2014-06-30)3 member; Special Committee on the Financial, Economic and Social Crisis (2009-10-08--2011-07-31)3 member; EPP (2009-11-25--2014-06-30)3 member; Delegation for relations with the Maghreb countries and the Arab Maghreb Union (2009-09-16--2014-06-30)3 substitute; LIBE (2009-07-16--2012-01-18)3 unknown; Il Popolo della Libertà (2009-07-14--2013-12-16)3
lpv:translated text	"I voted in favour of Mrs McAvan’s report, inasmuch as I believe that European policy coordination in the area of public health is necessary. The monitoring of medicinal products means ensuring health safety and improving the effectiveness of the European health system. There is a duty to citizens of the Union to monitor the safety of medicinal products once they have come on to the market, as well as improving European legislation with regard to the aims of Mrs McAvan’s report. I agree with the structure and message of the report, aimed at closer cooperation between Member States, the establishment of a pharmacovigilance risk assessment advisory committee, and greater transparency in the pharmacovigilance system committed to listening to individual citizens, so as to facilitate the withdrawal of dangerous medicinal products from the market and form the basis for a better health system."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph